Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04570761
Other study ID # DR200077
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 11, 2021
Est. completion date March 2024

Study information

Verified date October 2023
Source University Hospital, Tours
Contact Anna-Chloé BALAGEAS, PhD
Phone 0234378952
Email a.balageas@chu-tours.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Alzheimer's disease (AD) is a neurodegenerative disorder affecting almost 6% of the world's population over the age of 65. This disease, in its most typical sporadic form, is characterized by an episodic memory impairment linked to a deficit in consolidation. Many studies indicate that sleep promotes this consolidation stage during the deep slow sleep stage by facilitating the transfer of information between the hippocampus and the neocortex. A method of acoustic brain stimulation at night by pink noises has been recently developed and has shown its effectiveness in strengthening memory consolidation in healthy volunteers. Actually, there is no study observing the effect of this new stimulation method on populations with neurodegenerative pathologies, in particular in AD for which this technique could potentially become a therapeutic option. The hypothesis is that of a strengthening of the memory consolidation capacities in subjects with AD as has been shown in healthy subjects.


Description:

Alzheimer's disease (AD) is a neurodegenerative disorder affecting almost 6% of the world's population over the age of 65. This disease, in its most typical sporadic form, is characterized by an episodic memory impairment linked to a deficit in consolidation. Many studies indicate that sleep promotes this consolidation stage during the deep slow sleep stage by facilitating the transfer of information between the hippocampus and the neocortex. A method of acoustic brain stimulation at night by pink noises has been recently developed and has shown its effectiveness in strengthening memory consolidation in healthy volunteers. Actually, there is no study observing the effect of this new stimulation method on populations with neurodegenerative pathologies, in particular in AD for which this technique could potentially become a therapeutic option. The hypothesis is that of a strengthening of the memory consolidation capacities in subjects with AD as has been shown in healthy subjects.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date March 2024
Est. primary completion date March 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria common to all participants: - Age> 50 years at the inclusion - Patient with regular sleep patterns - Patient having given written consent - Patient affiliated to a social security regimen Inclusion criteria for subjects with Alzheimer's disease: - Patient with a beginning Alzheimer's disease defined according to the criteria of the National Institute on Aging-Alzheimer's Association or carriers of a prodromal Alzheimer's disease defined according to the criteria of the International Working Group IWG-2; the diagnosis must be supported by brain imaging and a blood test carried out in routine care - MMSE score = 24 Inclusion criteria for healthy volunteers: - Absence of neurodegenerative pathologies - Matched in age (+/- 5 years) and in sex with a patient Non-inclusion criteria common to all participants: - Psychiatric pathologies (except depression or anxiety disorders stabilized for more than 3 months) - History of pathology which may have consequences on cognitive functioning and / or sleep: brain tumor, constituted stroke, epilepsy, head trauma (with clinical or parenchymal sequelae objectified on brain imagery), brain surgery - Any significant comorbidity likely to constitute a confounding factor according to the clinician - Psychotropic treatments introduced or modified <3 months before inclusion - Hypnotic and / or sedative treatments - Chronic consumption of alcohol or drugs - Legal incapacity and / or other circumstance rendering the patient unable to understand the nature, objective or consequences of the study - Major under guardianship or curatorship - Patient not French-speaking by birth or illiterate Exclusion Criteria common to all participants: - Sleep disorders defined by a score> 5 on the Pittsburg sleep quality index (PSQI) - A score> 10 on the Epworth sleepiness index

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Dreem headband
acoustic stimulation
Dreem headband
acoustic stimulation

Locations

Country Name City State
France University Hospital of Tours Tours

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Tours

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. Day 7
Primary difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. Day 8
Primary difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. Day 14
Primary difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. Day 15
Secondary Number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. Day 7
Secondary Number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. Day 8
Secondary Number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. Day 14
Secondary Number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. Day 15
Secondary The memory complaint for Mc Nair's Questionnaire score from 0 to 156.156 control of a bad score. The variation between J0 and J15 will be studied. Baseline
Secondary Psychoaffective aspects (Depression) for MADRS (Montgomery Asberg Depression Rating Scale) score from 0 to 60.60 control of a bad score. The variation between J0 and J15 will be studied. Baseline
Secondary Psychoaffective aspects (Anxiety) for HAMA (Hamilton Anxiety) score from 0 to 56.56 control of a bad score. The variation between J0 and J15 will be studied. Baseline
Secondary Quality of sleep for Pittsburgh Index (PSQI) It is more an index of tolerance than efficiency. If the score is higher, the tolerance is lower. Baseline
Secondary The memory complaint for Mc Nair's Questionnaire score from 0 to 156.156 control of a bad score. The variation between J0 and J15 will be studied. Day 15
Secondary Psychoaffective aspects (Depression) for MADRS (Montgomery Asberg Depression Rating Scale) score from 0 to 60.60 control of a bad score. The variation between J0 and J15 will be studied. Day 15
Secondary Psychoaffective aspects (Anxiety) for HAMA (Hamilton Anxiety) score from 0 to 56.56 control of a bad score. The variation between J0 and J15 will be studied. Day 15
Secondary Quality of sleep for Pittsburgh Index (PSQI) It is more an index of tolerance than efficiency. If the score is higher, the tolerance is lower. Day 15
Secondary amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition gross variation in the amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition, on an ambulatory EEG device Day 7
Secondary amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition gross variation in the amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition, on an ambulatory EEG device Day 8
Secondary amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition gross variation in the amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition, on an ambulatory EEG device Day 14
Secondary amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition gross variation in the amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition, on an ambulatory EEG device Day 15
See also
  Status Clinical Trial Phase
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Recruiting NCT02854033 - Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Completed NCT02681172 - Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD Phase 4
Completed NCT02593318 - Trial of Oxaloacetate in Alzheimer's Disease (TOAD) Phase 1
Completed NCT02264899 - MEMENTO-VAScular COmponents of Dementia N/A
Completed NCT02531360 - Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies Phase 0
Not yet recruiting NCT05592678 - δ in Dementia Clinical Trials Phase 2/Phase 3
Not yet recruiting NCT05558709 - Social-cognitive Functioning: Validation of a New Neuropsychological Test N/A
Recruiting NCT05059158 - Amyloid-β Clearance Mechanisms in Alzheimer's Disease
Recruiting NCT02832921 - Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk N/A
Completed NCT02370524 - Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease Phase 1
Completed NCT01780519 - The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms Phase 1
Completed NCT02103894 - Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects Phase 1
Completed NCT03802162 - A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 Phase 1
Completed NCT01231971 - Alzheimer's Disease Neuroimaging Initiative 2
Recruiting NCT05291234 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease Phase 2
Active, not recruiting NCT05771428 - Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease Phase 2
Recruiting NCT06114745 - A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Phase 1